

A Ringed Enigma

The Clinical Spectrum of Granuloma Annulare

Zisansha Zahirsha and Eden Lake

ABSTRACT: Granuloma annulare is a poorly understood disease typically presenting as localized, nonscaly, annular plaques on the dorsal extremities. Clinical variants, such as generalized, patch, perforating, and subcutaneous types, exist. Therefore, granuloma annulare has a broad range of clinical morphologies and presentations. Knowledge of the clinical features, prognosis, and treatment options of the disease is critical for providers to appropriately diagnose and manage the condition.

Key words: Granuloma Annulare, Clinical Presentation, Clinical Spectrum, Diagnosis, Treatment

Granuloma annulare is a benign, idiopathic disease with a broad clinical presentation. The aim of this evidence-based review is to bring awareness to the entity of granuloma annulare and highlight its clinical spectrum.

EPIDEMIOLOGY

Granuloma annulare is relatively rare with a prevalence and incidence of approximately 0.1%–0.4% (Schmieder & Schmieder, 2019). Greater than two thirds of patients are aged 30 years or younger, and granuloma annulare has a higher incidence among female patients (Rubin & Rosenbach, 2019; Schmieder & Schmieder, 2019).

PATHOGENESIS

The pathogenesis of granuloma annulare is unknown. Hypotheses, including an immune-mediated type III hypersensitivity reaction causing a chronic vasculitis, elastic fiber degeneration, or a Th1 cell-mediated process, have all been speculated as the cause of granuloma annulare (Hanna,

Moreno-Merlo, & Andrighetti, 1999; Mempel et al., 2002; Piette & Rosenbach, 2016). In addition, granuloma annulare, especially the generalized variant, has reported associations with systemic diseases such as diabetes mellitus, HIV, and rheumatoid arthritis (Maschio et al., 2013; Studer, Calza, & Saurat, 1996; Toro, Chu, & Yen, 1999).

CLINICAL FEATURES

The presentation of granuloma annulare can vary drastically. In approximately 75% of cases, it presents as a localized variant with asymptomatic, nonscaly, annular papules or plaques with a rope-like border symmetrically distributed on the dorsal distal extremities (Figure 1A–C), wrists, or ankles (Hsu, Lehner, & Chang, 1999; Muhlbauer, 1980; Schmieder & Schmieder, 2019). Up to 15% of cases involve widespread erythematous annular plaques or micropapules scattered throughout the trunk and extremities, known as generalized granuloma annulare (Dabski & Winkelmann, 1989; Schmieder & Schmieder, 2019; Wolff, Johnson, Saavedra, & Roh, 2017). However, granuloma annulare can present as patches, cutaneous cords, or even subcutaneous nodules without epidermal changes on the lower legs, head, and buttocks (Mutasim & Bridges, 2000; Requena & Fernandez-Figueras, 2007; Verneuil, Dompormartin, Comoz, Pasquier, & Leroy, 2001). A perforating granuloma annulare variant has been reported primarily in children, presenting as erythematous papules progressing to yellow umbilicated papules with




FIGURE 1. (A–C) Granuloma annulare presenting as erythematous, annular, nonscaly pink papules with a rope-like border on the bilateral dorsal forearms.

Zisansha Zahirsha, BA, Saint Louis University School of Medicine, St. Louis, MO.

Eden Lake, MD, Division of Dermatology, Loyola University, Maywood, IL.

The authors declare no conflict of interest.

Correspondence concerning this article should be addressed to Zisansha Zahirsha, BA, 7118 Lindenwood Place, St. Louis, MO 63109. E-mail: zisansha.zahirsha@health.slu.edu

Copyright © 2020 by the Dermatology Nurses' Association.

DOI: 10.1097/JDN.0000000000000525



FIGURE 2. Granuloma annulare presenting as erythematous annular plaques with a pink scaly border and hyperpigmented central clearing on the upper chest.

discharge, crusting, and ulceration (Samlaska, Sandberg, Maggio, & Sakas, 1992). The distribution of granuloma annulare is usually the trunk (Figure 2) or extremities, but it can affect most areas of the body, including the genitals.

DERMATOPATHOLOGY

Diagnosis of granuloma annulare is made clinically or histologically. Histopathology shows a granulomatous inflammatory pattern in the superficial and mid-dermis with necrobiosis of connective tissue (Chatterjee, Kaur, Punia, Bhalla, & Handa, 2018; Wolff et al., 2017). In the areas of collagen degeneration, mucin is typically present, which can be best visualized with Alcian blue or colloidal iron stains (Tronnier & Mitteldorf, 2015).

DIFFERENTIAL DIAGNOSIS

The broad clinical presentation of granuloma annulare leads to a wide-ranging differential diagnosis depending on the variant visualized. In the presentation of a classic annular papule or plaque, tinea corporis, annular lichen planus, cutaneous sarcoidosis, erythema annulare centrifugum, and nodular tertiary syphilis can be considered. Generalized granuloma annulare can present similarly to arthropod bites, id reaction (autoeczematization), Sweet syndrome, or eruptive xanthomas. Rheumatoid nodules, subcutaneous sarcoidosis, and deep fungal infections are also included in the differential diagnosis for the subcutaneous variant. Finally, perforating granuloma annulare can be confused with other perforating diseases such as perforating folliculitis or perforating cutaneous sarcoidosis.

TREATMENT

Most cases of granuloma annulare are localized with spontaneous resolution. Approximately 50% of cases of localized granuloma annulare resolve in 2 years, and about 80% of cases resolve in 9 years (Wells & Smith, 1963). However, granuloma annulare may persist and require treatment (Mazzatenta, Ghilardi, & Grazzini, 2010). There are no standardized guidelines on the management of granuloma annulare as current

literature on the efficacy of treatment options is primarily restricted to case reports and small case series (Lukács, Schliemann, & Elsner, 2015).

Topical and intralesional corticosteroids are considered first-line therapies (Brey, Malone, & Callen, 2006; Rallis, Stavropoulou, & Korfitis, 2009; Seif-El-Nasr & El-Komy, 1962; Volden, 1992). Other treatment options with reported success include psoralen and ultraviolet A light therapy, niacinamide, isotretinoin, topical calcineurin inhibitors, and pentoxifylline (Baskan, Turan, & Tunali, 2007; Buendia-Eisman, Ruiz-Villaverde, Blasco-Melguizo, & Serrano-Ortega, 2003; Harth & Richard, 1993; Hindson, Spiro, & Cochrane, 1988; Jain & Stephens, 2004; Ma & Medenica, 1983; Rigopoulos et al., 2005; Rubel, Wood, Rosen, & Jopp-McKay, 1993; Tang, Chong, & Lo, 1996).

DISCUSSION

In conclusion, although we have a limited understanding of the cause of granuloma annulare, providers should be aware of its broad clinical spectrum as it is imperative for an appropriate diagnosis. The five variants of granuloma annulare, namely, localized, generalized, patch type, perforating, and subcutaneous, lead to numerous clinical scenarios in which a diagnosis of granuloma annulare should be considered. Granuloma annulare is typically idiopathic without inciting factors and can present on visible parts of the body. Because of this, although the lesions are often asymptomatic, the clinical findings can be alarming for a patient. Knowledge of the self-limiting nature of most granuloma annulare cases and possible treatment options allows for enhanced education, counseling, and management. Future studies should aim to further elucidate the etiology of granuloma annulare and determine the effectiveness of treatment options as there are significant gaps in the literature regarding these topics. ■

REFERENCES

- Baskan, E. B., Turan, A., & Tunali, S. (2007). A case of generalized granuloma annulare with myelodysplastic syndrome: Successful treatment with systemic isotretinoin and topical pimecrolimus 1% cream combination. *Journal of the European Academy of Dermatology and Venereology*, 21, 693–695.
- Brey, N. V., Malone, J., & Callen, J. P. (2006). Acute-onset, painful acral granuloma annulare: A report of 4 cases and a discussion of the clinical and histologic spectrum of the disease. *Arch Dermatol*, 142(1), 49–54.
- Buendia-Eisman, A., Ruiz-Villaverde, R., Blasco-Melguizo, J., & Serrano-Ortega, S. (2003). Generalized annular granuloma: Response to isotretinoin. *International Journal of Dermatology*, 42(4), 321–322.
- Chatterjee, D., Kaur, M., Punia, R., Bhalla, M., & Handa, U. (2018). Evaluating the unusual histological aspects of granuloma annulare: A study of 30 cases. *Indian Dermatology Online Journal*, 9(6), 409–413.
- Dabski, K., & Winkelmann, R. K. (1989). Generalized granuloma annulare: Clinical and laboratory findings in 100 patients. *Journal of the American Academy of Dermatology*, 20(1), 39.
- Hanna, W. M., Moreno-Merlo, F., & Andrighetti, L. (1999). Granuloma annulare: An elastic tissue disease? Case report and literature review. *Ultrastructural Pathology*, 23(1), 33–38.
- Harth, W., & Richard, G. (1993). Retinoids in therapy of granuloma annulare disseminatum. *Hautarzt*, 44, 693–698.
- Hindson, T. C., Spiro, J. G., & Cochrane, H. (1988). PUVA therapy of diffuse granuloma annulare. *Clinical and Experimental Dermatology*, 13, 26–27.
- Hsu, S., Lehner, A. C., & Chang, J. R. (1999). Granuloma annulare localized to the palms. *Journal of the American Academy of Dermatology*, 41(2, Pt. 2), 287–288.

- Jain, S., & Stephens, C. J. M. (2004). Successful treatment of disseminated granuloma annulare with topical tacrolimus. *British Journal of Dermatology*, 150, 1042–1043.
- Lukács, J., Schliemann, S., & Elsner, P. (2015). Treatment of generalized granuloma annulare—A systematic review. *Journal of the European Academy of Dermatology and Venereology*, 29(8), 1467–1480.
- Ma, A., & Medenica, M. (1983). Response of generalized granuloma annulare to high-dose niacinamide. *Archives of Dermatology*, 119, 836–839.
- Maschio, M., Marigliano, M., Sabbion, A., Morandi, A., Schena, D., Colato, C., & Maffei, C. (2013). A rare case of granuloma annulare in a 5-year-old child with type 1 diabetes and autoimmune thyroiditis. *The American Journal of Dermatopathology*, 35(3), 385–387.
- Mazzatenta, C., Ghilardi, A., & Grazzini, M. (2010). Treatment of disseminated granuloma annulare with allopurinol: Case report. *Dermatologic Therapy*, 23(Suppl. 1), S24–S27.
- Mempel, M., Musette, P., Flageul, B., Schnopp, C., Remling, R., Gachelin, G., ... Abeck, D. (2002). T-cell receptor repertoire and cytokine pattern in granuloma annulare: Defining a particular type of cutaneous inflammation. *Journal of Investigative Dermatology*, 118(6), 957–966.
- Muhlbauer, J. E. (1980). Granuloma annulare. *Journal of the American Academy of Dermatology*, 3(3), 217.
- Mutasim, D. F., & Bridges, A. G. (2000). Patch granuloma annulare: Clinicopathologic study of 6 patients. *Journal of the American Academy of Dermatology*, 42(3), 417.
- Piette, E. W., & Rosenbach, M. (2016). Granuloma annulare. *Journal of the American Academy of Dermatology*, 75(3), 467–479.
- Rallis, E., Stavropoulou, E., & Korfitis, C. (2009). Granuloma annulare of childhood successfully treated with potent topical corticosteroids previously unresponsive to tacrolimus ointment 0.1%: Report of three cases. *Clinical and Experimental Dermatology*, 34(7), e475.
- Requena, L., & Fernandez-Figueras, M. T. (2007). Subcutaneous granuloma annulare. *Seminars in Cutaneous Medicine and Surgery*, 26(2), 96.
- Rigopoulos, D., Prantsidis, A., Christofidou, E., Ioannides, D., Gregoriou, S., & Katsambas, A. (2005). Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. *British Journal of Dermatology*, 152, 1364–1365.
- Rubel, D. M., Wood, G., Rosen, R., & Jopp-McKay, A. (1993). Generalised granuloma annulare successfully treated with pentoxifylline. *The Australasian Journal of Dermatology*, 34, 103–108.
- Rubin, C. B., & Rosenbach, M. (2019). Granuloma annulare: A retrospective series of 133 patients. *Cutis*, 103(2), 102–106.
- Samlaska, C. P., Sandberg, G. D., Maggio, K. L., & Sakas, E. L. (1992). Generalized perforating granuloma annulare. *Journal of the American Academy of Dermatology*, 27(2, Pt. 2), 319–322.
- Schmieder, S. J., & Schmieder, G. J. (2019). *Granuloma annulare*. Treasure Island, FL: StatPearls.
- Seif-El-Nasr, H., & El-Komy, H. M. (1962). Granuloma annulare. Report of a case treated successfully by intralesional triamcinolone injection. *The Journal of the Egyptian Medical Association*, 45, 105–106.
- Studer, E. M., Calza, A. M., & Saurat, J. H. (1996). Precipitating factors and associated diseases in 84 patients with granuloma annulare: A retrospective study. *Dermatology*, 193, 364–368.
- Tang, W. Y., Chong, L. Y., & Lo, K. K. (1996). Resolution of generalized granuloma annulare with isotretinoin therapy. *International Journal of Dermatology*, 35, 455–456.
- Toro, J. R., Chu, P., & Yen, T. S. (1999). Granuloma annulare and human immunodeficiency virus infection. *Archives of Dermatology*, 135(11), 1341–1346.
- Tronnier, M., & Mitteldorf, C. (2015). Histologic features of granulomatous skin diseases. Part 1: Non-infectious granulomatous disorder. *Journal Der Deutschen Dermatologischen Gesellschaft*, 13(3), 211–216.
- Verneuil, L., Dompartin, A., Comoz, F., Pasquier, C. J., & Leroy, D. (2001). Interstitial granulomatous dermatitis with cutaneous cords and arthritis: A disorder associated with autoantibodies. *Journal of the American Academy of Dermatology*, 45(2), 286–291.
- Volden, G. (1992). Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. *Acta Dermato-Venereologica*, 72(1), 69–71.
- Wells, R. S., & Smith, M. A. (1963). The natural history of granuloma annulare. *British Journal of Dermatology*, 75, 199–205.
- Wolff, K., Johnson, R., Saavedra, A., & Roh, E. (2017). *Fitzpatrick's color atlas and synopsis of clinical dermatology*. New York, NY: McGraw-Hill Education.

For more than 54 additional continuing education articles related to dermatologic conditions, go to NursingCenter.com.

Instructions:

- Read the article. The test for this CE activity can only be taken online at <http://www.nursingcenter.com>. Tests can no longer be mailed or faxed.
- You will need to create (it's free!) and login to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you.
- There is only one correct answer for each question. If you pass, you will receive a certificate of earned contact hours and answer key. If you fail, you have the option of taking the test again at no additional cost.
- A passing score for this test is 7 correct answers.

- Questions? Contact Lippincott Professional Development: 1-800-787-8985.

Registration Deadline: March 4, 2022

Provider Accreditation:

Lippincott Professional Development will award 1.0 contact hour for this continuing nursing education activity.

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider

Number CEP 11749 for 1.0 contact hour. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia, Georgia, and Florida #50-1223.

Your certificate is valid in all states.

Disclosure Statement:

The authors and planners have disclosed that they have no financial relationships related to this article.

Payment and Discounts:

- The registration fee for this test is \$10 for members; \$20 for nonmembers.